UAB Alzheimer's Disease Center Core Cohort - Imaging Substudy

The primary objective of this study is to measure the concentration and the regional brain
distribution of pathologic amyloid deposition using the PET tracer [C-11]PiB in participants
in the UAB-ADC cohort. The amount and distribution of [C-11]PiB in the brain will be
correlated to demographic, clinical, genetic, and biospecimen data acquired through the
separate ongoing UAB-ADC study. Assessment of interactions between race and vascular risk
factors, brain amyloid levels measured with [C-11]PiB-PET, and cognitive status will be the
primary outcome of this imaging study. As a secondary aim, the investigators will assess the
ability of the early flow frames from [C-11]PiB-PET and brain volumetric measurements with
MRI to serve as a marker of neuronal injury and to predict cognitive status in conjunction
with the amyloid-PET results.

Inclusion Criteria:

- 1. Enrollment in the UAB-ADC study under a separate IRB-approved research protocol
(IRB-300000169).

2. Negative urine or serum B-hCG test within 2 days of [C-11]PiB administration in women of
child bearing potential. Women who are post-menopausal with at least 1 year since last
menses or documented surgical sterilization will not require pregnancy testing.

Exclusion Criteria:

1. Meets any exclusion criteria for the UAB-ADC study (IRB-300000169).

2. Inability or contraindication for undergoing MRI and/or PET imaging

3. Inability to participate in the imaging studies due to severity of dementia